Phaseline

Companies › Cytopeutics Sdn. Bhd.

Cytopeutics Sdn. Bhd.: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Neuroncell-EX
Umbilical cord mesenchymal stem cells (UCMSCs)
–Phase 2Acute Ischemic StrokeNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06129175Neuroncell-EXPhase 2Acute Ischemic StrokeNeurologyNov 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

NKGen Biotech Sandoz Merz Pharmaceuticals Lupin Neurona Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.